Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Research Rheum

COVID-19 Pandemic Leads Big Drugmakers to Hit Pause on Clinical Trials

Reuters Staff  |  

(Reuters)—U.S. drugmakers Eli Lilly and Co. and Bristol Myers Squibb said they are delaying the start of new clinical trials in part to free up doctors and healthcare facilities to deal with the surge in patients infected with the new coronavirus. Lilly and Bristol are the biggest drugmakers yet to announce clinical trial delays in…

A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

  |  

Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.

The Rheumatology Research Foundation Welcomes New Leaders

  |  

The Rheumatology Research Foundation has appointed S. Louis Bridges Jr., MD, PhD, to serve as president for a two-year term. Dr. Bridges has served as the director of the University of Alabama–Birmingham (UAB) Division of Clinical Immunology and Rheumatology since 2009. He is also the director of the UAB Comprehensive Arthritis, Musculo­skeletal, Bone and Autoimmunity…

5 Challenges in the Treatment & Diagnosis of Lupus

  |  

A recent study published in Lupus Science & Medicine lays out five of the top barriers impeding progress in lupus diagnosis and treatment.1 The Addressing Lupus Pillars for Health Advancement project (ALPHA), led by the Lupus Foundation of America (LFA), researchers at the Tufts School of Medicine Center for the Study of Drug Development (Tufts…

Tero Vesalainen / shutterstock.com

Study Finds an Indirect Association Between Sleep & Inflammation

  |  

In a study in Arthritis Care & Research, researchers showed an indirect association between osteoarthritis (OA) and sleep health in older men.1 In those participants with OA, the condition is associated with poorer sleep health, as well as a 16% higher incidence of elevated C-reactive protein and 12% higher odds of having elevated interleukin 6….

The Third Choice: The Predatory Journal Scam

  |  

“Greetings of the day!” My email account used to be flooded by these cheerful salutations, referring to me as an esteemed colleague or a thought leader. I have to admit: at first, I enjoyed receiving these messages. Normally, when I log into my email account, I’m greeted by messages—punctuated by red, capital letters—that announce dire…

Emerging Biomarkers for Lupus

  |  

ATLANTA—When it comes to identifying reliable biomarkers that can predict worsening illness or help point to proper treatment, it’s hard to imagine a more vexing disease than systemic lupus erythematosus (SLE), said Jill P. Buyon, MD, director of the Lupus Center at New York University Langone Medical Center, in the 2019 ACR/ARP Annual Meeting session…

PAD4 Antibodies May Help Predict Treatment Response in Rheumatoid Arthritis

  |  

A study published in Arthritis & Rheumatology highlights how the presence of autoantibodies to peptidylarginine deiminase (PAD) may eventually be used to influence treatment decisions in the management of rheumatoid arthritis (RA), sharpening our understanding of disease subtypes.1 Although follow-up prospective studies are needed, these findings underline some intriguing areas for future investigations in immunobiology….